PPH Legal Blog

A 29 year old semi-pro football player was diagnosed with Primary Pulmonary Hypertension (PPH) after taking the diet drug Adapex for roughly two years.
In 2003, the man was prescribed medication for high blood pressure. This medicine kept everything under control until a different doctor prescribed the diet-drug Adapex in 2005. Then, not only did his […]

[Read more →]

Encysive Pharmaceuticals announced sales guidlines for 2007 and 2008 for the first once-daily oral treatment used to treat Primary Pulmonary Hypertension and Primary Arterial Hypertension in the EU.
Thelin was approved for sale in the EU in August of 2006. In 2007, it was given approval for sale in Italy which means that the drug is […]

[Read more →]

GlaxoSmithKline, the maker of the troubled diabetes drug Avandia, has to delay the start of studies to determine whether Avandia can help to treat Alzheimer’s. The delay is expected to deprive GSK of $300 million in revenues.
The delay in studies is due to the unwillingness of patients to volunteer for the trials after Avandia’s other […]

[Read more →]

When pulmonary hypertension occurs in the absence of a known cause, it is referred to as primary pulmonary hypertension (PPH). Pulmonary hypertension is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) rises above normal levels and […]

[Read more →]

Two major healthcare providers in the United States have dropped the controversial drug Avandia from their lists of approved medicines for Type II Diabetes.
The removal of Avandia from Prime Therapeutics and HealthTrans follow the Department of Veterans Affairs dropping the drug from their formularies. These actions may further drop sales of Avandia. Sales of Avandia […]

[Read more →]